Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Åndedrettsmekanikk for å levere individualisert eksogent overflateaktivt middel (REMEDIES)

2. november 2026 oppdatert av: Anna Lavizzari, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

En randomisert kontrollert prøvelse av oscillerende mekanikk versus oksygeneringsbaserte kriterier for overflateaktivt terapi

This study is an interventional, non-pharmacological, multicentric, randomized, controlled, superiority, non-profit study. Its primary objective is to evaluate if the administration of surfactant based on FOT assessment will allow a 5-day reduction in the duration of respiratory support as compared to standard practice in preterm infants between 27+0 and 32+6 weeks' gestation. The secondary objectives are:

  1. to determine if a lung mechanics-based approach for administering surfactant will change treatment timing; and
  2. to assess the impact of the novel approach on other neonatal general outcomes. The study will take place within the neonatal intensive care units. Non-invasive respiratory support will be delivered by nasal CPAP with a starting pressure of 5-8 cmH2O. FiO2 will be titrated in order to achieve the target SpO2 91-95%.

Infants matching the clinical criteria for inclusion will be randomized in two arms following the current data protection and confidentiality regulations. Central, computer-generated randomization (allocation 1:1) with variable block sizes according to gestational age will be used. Infants will be stratified according to gestational age (27+0 -28+6 weeks; 29+0 -30+6 weeks; 31+0 -32+6 weeks) and center.

Study Arms:

A) Surfactant administration following oxygenation-based criteria (clinical assessment) (control) B) Surfactant administration following both lung mechanics assessment OR oxygenation-based criteria (clinical assessment) (intervention).

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

458

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

      • Milan, Italia
        • Rekruttering
        • Fondazione IRCCs Cà Granda Ospedale Maggiore Policlinico
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

6 måneder til 7 måneder (Barn)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Gestational age (GA) ≥ 27+0 and < 33+0 weeks
  2. Spontaneously breathing infants, requiring non-invasive respiratory support (nasal CPAP or bilevel nasal CPAP). Criteria for commencement of non-invasive respiratory support: FiO2 >0.30 for target SpO2 88-93% or Silverman score ≥ 5.
  3. Inborn
  4. Written parental consent obtained
  5. Administration of Caffeine bolus 20 mg/kg IV or PO as per standard care

Exclusion Criteria:

  1. Major congenital anomalies
  2. Need of intubation in delivery suite according to the AAP guidelines for neonatal resuscitation or early at the admission in NICU (within one hour from birth).
  3. Surfactant therapy prior to the study entry
  4. Severe birth asphyxia, defined by APGAR score ≤ 5 at 10 minutes after birth OR continued need for resuscitation 10 minutes after birth OR pH < 7.0 or base excess (BE) < -12 mmol/l on umbilical cord or on an arterial or capillary blood sample obtained within 1 hour from birth OR moderate to severe encephalopathy
  5. Respiratory failure secondary to conditions other that RDS as identified by lung imaging (air leaks, lung malformations…)
  6. Any clinical condition which may place the infants at undue risk as deemed by clinicians
  7. Participation to trials with competitive outcomes or likely to have an impact on the primary outcome of the study
  8. Outborn patients

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Trippel

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: A/Control

Surfactant administration following clinical assessment

Surfactant is administered following oxygenation-based criteria

Eksperimentell: B/Intervention

Surfactant administration following both lung mechanics assessment and clinical assessment

Surfactant is administered following oxygenation-based criteria and if the Xrs is ≤ -23.3 cmH2O*s /L

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Days of respiratory support
Tidsramme: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of days of required respiratory support

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
First surfactant administration
Tidsramme: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Time of first surfactant administration (in hours)

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Days of non-invasive respiratory support
Tidsramme: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of days of non-invasive respiratory support

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Days of invasive respiratory support
Tidsramme: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of days of invasive respiratory support

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Patients intubated and mechanically ventilated
Tidsramme: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of patients intubated and mechanically ventilated

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Patients receiving multiple surfactant doses
Tidsramme: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of patients receiving multiple surfactant doses

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Days on supplemental oxygen
Tidsramme: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of days on supplemental oxygen

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Total cumulative oxygen exposure
Tidsramme: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Total cumulative oxygen exposure computed as the time integral of the FiO2 values

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Infants receiving more than 28 days of respiratory support
Tidsramme: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of infants receiving more than 28 days of respiratory support

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Infants developing BPD
Tidsramme: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of infants developing BPD according to the definition by NICHD 2016

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Infants developing air-leaks
Tidsramme: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of infants developing air-leaks

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Infants developing prematurity-associated complications
Tidsramme: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of infants developing prematurity-associated complications (severe intraventricular haemorrhage (IVH), periventricular leukomalacia (PVL), necrotizing enterocolitis (NEC), sepsis, retinopathy of prematurity (ROP), patent ductus arteriosus requiring pharmacological or surgical treatment)

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Infants discharged home with oxygen or respiratory support
Tidsramme: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of infants discharged home with oxygen or respiratory support

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Days to achieve full-enteral feeding
Tidsramme: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of days to achieve full-enteral feeding (160 ml/kg/day of milk intake)

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Days of hospitalization
Tidsramme: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of days of hospitalization

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Infants receiving postnatal steroids
Tidsramme: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of infants receiving postnatal steroids

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

15. desember 2023

Primær fullføring (Antatt)

30. mai 2028

Studiet fullført (Antatt)

31. desember 2028

Datoer for studieregistrering

Først innsendt

9. desember 2022

Først innsendt som oppfylte QC-kriteriene

28. mars 2023

Først lagt ut (Faktiske)

30. mars 2023

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

5. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

2. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere